6
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      An Update on Mesoporous Silica Nanoparticle Applications in Nanomedicine

      review-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Abstract

          The efficient and safe delivery of therapeutic drugs, proteins, and nucleic acids are essential for meaningful therapeutic benefits. The field of nanomedicine shows promising implications in the development of therapeutics by delivering diagnostic and therapeutic compounds. Nanomedicine development has led to significant advances in the design and engineering of nanocarrier systems with supra-molecular structures. Smart mesoporous silica nanoparticles (MSNs), with excellent biocompatibility, tunable physicochemical properties, and site-specific functionalization, offer efficient and high loading capacity as well as robust and targeted delivery of a variety of payloads in a controlled fashion. Such unique nanocarriers should have great potential for challenging biomedical applications, such as tissue engineering, bioimaging techniques, stem cell research, and cancer therapies. However, in vivo applications of these nanocarriers should be further validated before clinical translation. To this end, this review begins with a brief introduction of MSNs properties, targeted drug delivery, and controlled release with a particular emphasis on their most recent diagnostic and therapeutic applications.

          Related collections

          Most cited references458

          • Record: found
          • Abstract: found
          • Article: not found

          Bacterial biofilms: a common cause of persistent infections.

          Bacteria that attach to surfaces aggregate in a hydrated polymeric matrix of their own synthesis to form biofilms. Formation of these sessile communities and their inherent resistance to antimicrobial agents are at the root of many persistent and chronic bacterial infections. Studies of biofilms have revealed differentiated, structured groups of cells with community properties. Recent advances in our understanding of the genetic and molecular basis of bacterial community behavior point to therapeutic targets that may provide a means for the control of biofilm infections.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Photodynamic therapy for cancer.

            The therapeutic properties of light have been known for thousands of years, but it was only in the last century that photodynamic therapy (PDT) was developed. At present, PDT is being tested in the clinic for use in oncology--to treat cancers of the head and neck, brain, lung, pancreas, intraperitoneal cavity, breast, prostate and skin. How does PDT work, and how can it be used to treat cancer and other diseases?
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Delivery technologies for cancer immunotherapy

              Immunotherapy has become a powerful clinical strategy for treating cancer. The number of immunotherapy drug approvals has been increasing, with numerous treatments in clinical and preclinical development. However, a key challenge in the broad implementation of immunotherapies for cancer remains the controlled modulation of the immune system, as these therapeutics have serious adverse effects including autoimmunity and nonspecific inflammation. Understanding howto increase the response rates to various classes of immunotherapy is key to improving efficacy and controlling these adverse effects. Advanced biomaterials and drug delivery systems, such as nanoparticles and the use of T cells to deliver therapies, could effectively harness immunotherapies and improve their potency while reducing toxic side effects. Here, we discuss these research advances, as well as the opportunities and challenges for integrating delivery technologies into cancer immunotherapy, and we critically analyse the outlook for these emerging areas.
                Bookmark

                Author and article information

                Contributors
                Role: Academic Editor
                Journal
                Pharmaceutics
                Pharmaceutics
                pharmaceutics
                Pharmaceutics
                MDPI
                1999-4923
                12 July 2021
                July 2021
                : 13
                : 7
                : 1067
                Affiliations
                [1 ]Department of Medical Research, Taipei Veterans General Hospital, Taipei 11217, Taiwan; elham.rastegar@ 123456gmail.com (E.R.); yj1007hsiao@ 123456yahoo.com (Y.-J.H.); jefflai8228@ 123456gmail.com (W.-Y.L.); tony1233000@ 123456yahoo.com.tw (Y.-H.L.); yangtienchun@ 123456gmail.com (T.-C.Y.); sjchen96@ 123456gmail.com (S.-J.C.)
                [2 ]Institute of Pharmacology, National Yang-Ming Chiao Tung University, Taipei 11217, Taiwan
                [3 ]School of Medicine, National Yang-Ming Chiao Tung University, Taipei 11217, Taiwan
                [4 ]Department of Ophthalmology, Taipei Veterans General Hospital, Taipei 11217, Taiwan
                [5 ]Department of Oncology, Taipei Veterans General Hospital, Taipei Veterans General Hospital, Taipei 11217, Taiwan; pihuang@ 123456vghtpe.gov.tw
                [6 ]Department of Chemistry, National Taiwan University, Taipei 10617, Taiwan
                Author notes
                Author information
                https://orcid.org/0000-0002-0783-605X
                https://orcid.org/0000-0002-1528-9252
                Article
                pharmaceutics-13-01067
                10.3390/pharmaceutics13071067
                8309088
                34371758
                b6edcbc4-5fce-463c-973e-d2f97347182a
                © 2021 by the authors.

                Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license ( https://creativecommons.org/licenses/by/4.0/).

                History
                : 24 May 2021
                : 05 July 2021
                Categories
                Review

                mesoporous silica nanoparticles,cancer therapy,bioimaging,tissue engineering,stem cell research

                Comments

                Comment on this article